AI Article Synopsis

  • Esophageal cancer often has a poor prognosis, and the common one-line treatment for metastatic cases is a combination of chemotherapy that includes platinum and 5-fluorouracil (5-FU).
  • A 74-year-old man with metastatic esophageal cancer was discovered to have a partial deficiency in the enzyme dihydropyrimidine dehydrogenase (DPD), which can increase the risk of severe side effects from 5-FU treatment.
  • The safe administration of 5-FU to the patient was made possible through therapeutic drug monitoring (TDM), emphasizing the significance of individualized dosing to minimize toxicities in patients with partial DPD deficiency.

Article Abstract

Esophageal cancer is a cancer with poor prognosis and the standard 1 line treatment for metastatic or recurrent EC is systemic chemotherapy with doublet chemotherapy based on platinum and 5-fluorouracil (5-FU). However, 5-FU could be a source of severe treatment-related toxicities due to deficiency of dihydropyrimidine dehydrogenase (DPD). In this case report, a 74-year-old man with metastatic esophageal cancer was found to have partial DPD deficiency based on uracilemia measurements (about 90 ng/mL). Despite this, 5-FU was safely administered thanks to therapeutic drug monitoring (TDM). The case report highlights the importance of TDM in administering 5-FU to patients with partial DPD deficiency, as it allows individualized dosing and prevents severe toxicity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319454PMC
http://dx.doi.org/10.3389/fonc.2023.1187052DOI Listing

Publication Analysis

Top Keywords

case report
12
partial dpd
12
dpd deficiency
12
esophageal cancer
8
report 5-fluorouracil
4
5-fluorouracil treatment
4
treatment patient
4
patient partial
4
dpd
4
deficiency
4

Similar Publications

Purpose: The NAB2::STAT6 fusion is predominantly associated with solitary fibrous tumors (SFTs) and is utilized in diagnosing SFTs through nuclear STAT6 protein overexpression. Recent studies expanded the phenotypic spectrum of NAB2::STAT6 rearranged neoplasms, including adamantinoma-like and teratocarcinosarcoma-like phenotypes. We report a case of a NAB2::STAT6 rearranged epithelial tumor exhibiting sebaceous differentiation in the parotid gland.

View Article and Find Full Text PDF

Background: Bilateral trigeminal neuralgia secondary to multiple sclerosis is an extremely rare condition. When Gasserian ganglion block is performed, it is necessary to achieve reliable long-term analgesic effects while avoiding treatment-related complications.

Case Presentation: A 49-year-old male with multiple sclerosis exhibited persistent dull pain and paroxysmal electric shock-like pain in his bilateral maxillary molars and mandible.

View Article and Find Full Text PDF

Recurrent Diffuse Tenosynovial Giant Cell Tumor of the Temporomandibular Joint.

Head Neck Pathol

January 2025

Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Purpose: Recurrent diffuse-type tenosynovial giant cell tumor: Clinical presentation, Diagnosis, and Management.

Background: Tenosynovial giant cell tumor (TGCT), is a neoplasm arising from synovial joints, bursae, or tendon sheaths. The initial clinical symptoms are vague and non-diagnostic.

View Article and Find Full Text PDF

ERCP Combined with EUS-BD for the Treatment of Malignant Biliary Obstruction Complicated by Cholangitis.

Dig Dis Sci

January 2025

Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Diseases, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, 100050, P.R. China.

View Article and Find Full Text PDF

Purpose: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor response to chemotherapy. High-frequency microsatellite instability (MSI-H) is a rare biological phenomenon in conventional PDAC, being more frequently described in tumors with medullary or mucinous features.

Methods And Results: In this manuscript, we report the case of a patient with an MSI-H pancreatic carcinoma with medullary features (medullary carcinoma of the pancreas-MCP) that achieved a complete pathological response after neoadjuvant modified FOLFIRINOX.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!